ValuEngine downgraded shares of Homology Medicines (NASDAQ:FIXX) from a buy rating to a hold rating in a research note issued to investors on Friday morning.
Other analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Homology Medicines from a hold rating to a buy rating and set a $19.00 target price on the stock in a research report on Thursday, August 16th. B. Riley started coverage on Homology Medicines in a research report on Friday, September 7th. They set a neutral rating and a $18.50 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Homology Medicines currently has a consensus rating of Hold and an average price target of $25.90.
Shares of FIXX traded up $0.47 during midday trading on Friday, reaching $24.98. 134,952 shares of the stock were exchanged, compared to its average volume of 140,074. Homology Medicines has a twelve month low of $15.07 and a twelve month high of $25.93.
Homology Medicines (NASDAQ:FIXX) last posted its earnings results on Tuesday, November 13th. The company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.03). The firm had revenue of $0.95 million during the quarter. As a group, equities research analysts anticipate that Homology Medicines will post -1.49 EPS for the current year.
In related news, major shareholder Ventures Iv L.P. 5Am sold 525,900 shares of the business’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $20.20, for a total value of $10,623,180.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN increased its position in Homology Medicines by 246.7% in the 3rd quarter. Wells Fargo & Company MN now owns 6,167 shares of the company’s stock valued at $141,000 after acquiring an additional 4,388 shares during the period. Rhumbline Advisers acquired a new position in Homology Medicines in the 3rd quarter valued at about $205,000. Bank of New York Mellon Corp acquired a new position in Homology Medicines in the 2nd quarter valued at about $558,000. Schwab Charles Investment Management Inc. acquired a new position in Homology Medicines in the 2nd quarter valued at about $998,000. Finally, Northern Trust Corp acquired a new position in Homology Medicines in the 2nd quarter valued at about $2,255,000. Hedge funds and other institutional investors own 53.41% of the company’s stock.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Read More: Catch-Up Contributions
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.